Jasper Therapeutics to Present Briquilimab Preclinical Data at ACAAI Annual Meeting

Jasper Therapeutics, Inc., a clinical stage biotechnology company based in Redwood City, California, is presenting promising data from preclinical studies on their novel antibody therapy, briquilimab, at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston. The event is being held from October 24-28, 2024.

Jasper Therapeutics, listed on Nasdaq under the symbol JSPR, is focused on the development of briquilimab, targeting c-Kit (CD117) to treat mast cell driven diseases, which include chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. Briquilimab functions by blocking stem cell factor from binding to the cell-surface receptor c-Kit. This action inhibits critical signaling pathways, resulting in mast cell depletion and reducing the underlying inflammatory responses associated with these conditions.

The company is showcasing data from several preclinical studies at the ACAAI meeting. According to Wendy Pang, M.D., Ph.D., Senior Vice President of Research and Translational Medicine at Jasper Therapeutics, the in-vitro and non-human primate data highlight briquilimab’s capacity to bind c-Kit and effectively deplete mast cells with high potency. These findings support the potential of briquilimab as a powerful therapeutic agent in treating mast cell related diseases.

The presentations are scheduled as follows:

1. Abstract titled "Briquilimab is Well-Tolerated and Effectively Depletes Tissue Resident Mast Cells in Non-Human Primates" will be presented on October 25, 2024, from 3:45 p.m. to 4:00 p.m. EDT at Exhibit Hall A.
2. Abstract titled "Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling, and Mast Cell (MC) Degranulation and Survival" is set for October 25, 2024, from 4:15 p.m. to 4:30 p.m. EDT at Exhibit Hall A.
3. Abstract titled "Briquilimab Potently Blocks Stem Cell Factor (SCF)/c-Kit Signaling in Primary Human Mast Cells" will be presented on October 25, 2024, from 4:30 p.m. to 4:45 p.m. EDT at Exhibit Hall A.

The presentation materials will be made available on the ACAAI website and the Jasper Therapeutics IR website.

Briquilimab, also known as a targeted aglycosylated monoclonal antibody, is currently undergoing clinical trials for the treatment of CSU and CIndU and is about to commence studies in patients with asthma. Additionally, briquilimab is being investigated for use in treating lower to intermediate risk myelodysplastic syndromes (LR-MDS) and as a conditioning agent for cell therapies in rare diseases such as severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), Fanconi anemia (FA), and sickle cell disease (SCD). To date, over 160 participants and healthy volunteers have been dosed with briquilimab, demonstrating both efficacy and a favorable safety profile.

Jasper Therapeutics continues to advance the development of briquilimab, aiming to provide effective treatment options for patients suffering from a range of mast cell and stem cell diseases. The company's ongoing research and clinical trials are crucial steps toward possibly transforming the therapeutic landscape for these conditions.